BR0015788A - Agentes anti-diabéticos - Google Patents
Agentes anti-diabéticosInfo
- Publication number
- BR0015788A BR0015788A BR0015788-0A BR0015788A BR0015788A BR 0015788 A BR0015788 A BR 0015788A BR 0015788 A BR0015788 A BR 0015788A BR 0015788 A BR0015788 A BR 0015788A
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- optionally substituted
- cow
- phenyl
- groups
- Prior art date
Links
- 239000003472 antidiabetic agent Substances 0.000 title abstract 2
- 229940125708 antidiabetic agent Drugs 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 2
- 208000002705 Glucose Intolerance Diseases 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000266 alpha-aminoacyl group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 abstract 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 abstract 1
- 201000009104 prediabetes syndrome Diseases 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Abstract
"AGENTES ANTI-DIABéTICOS". Compostos que são derivados de 1-( 2'-aminoacil )-2-cianopirrolidina de acordo com a fórmula geral ( 1 ) são inibidores da DP-IV para o tratamento da tolerância prejudicada à glicose ou do diabetes do tipo 2; nos quais A é selecionado a partir de grupos ( 2,3 e 4) X é selecionado a partir de grupos amino acila que correspondem aos aminoácidos naturais, grupos acila R^ 3^CO, grupos R^ 4^COOC( R^ 5^ )( R^ 6^ )OCO metoxicarbonila, etoxicarbonila e benziloxicarbonila; R^ 1^ é selecionado a partir de H, um resíduo de C~ 1~-C~ 6~ alquila, ( CH~ 2~ )~ a~ NH^ 1^, ( CH~ 2~ )~ b~COW^ 2^ (CH~ 2~)~ c~OW^ 3^, CH(Me)OW^ 4^ (CH~ 2~)~ d~-C~ 6 ~H~ 4~W^ 5^ , e ( CH~ 2~ )~ e~SW^ 6^, em que a é de 2 a 5,b é de 1 a 4, c é de 1 a 2, d é de 1 a 2, e é de 1 a 3, W^ 1^ é COW^ 6^ COW^ 6^ OU SO~ 2~W^ 6^, W^ 2^ é OH, NH~ 2~, OW^ 6^ ou NHW^ 6^ W^ 3^ é H OU W^ 6^ W^ 4^ é H OU W^ 6^ W^ 5^ é H, OH ou Ome, e W^ 6^ é C~ 1~ - C~ 6~ alquila, fenila opcionalmente substituída, heteroarila opcionalmente substituída ou benzila e R^ 2^ é selecionado a partir de H e (CH~ 2~)~ n~-C~ 5~H~ 3~N-Y, em que n é de 2 a 4 e Y é H, F, CL, NO~ 2~ ou CN, ou R^ 1^ e R^ 2^ em conjunto são -(CH~ 2~)p onde p é 3 ou 4; R^ 3^ é selecionado a partir de H, C~ 1~ C~ 6~ alquila e fenila; R^ 4^ é selecionado a partir de H, C~ 1~ - C~ 6~ alquila, benzila e fenila substituída de modo opcional; R^ 5^ e R^ 6^ são cada um de forma independente selecionados a partir de H e C~ 1~ - C~ 6~ alquila ou em conjunto são -(CH~ 2~)~ m~- onde m é de 4 a 6; R^ 7^ é selecionado a partir de piridila e fenila substituída de modo opcional; R^ 8^ é selecionado a partir de H e C~ 1~ - C~ 3~ alquila; e R^ 9^ é selecionado a partir de H, C~ 1~ - C~ 6~ alquila, C~ 1~ - C~ 6~ alcóxi e fenila.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9928330.1A GB9928330D0 (en) | 1999-11-30 | 1999-11-30 | Novel antidiabetic agents |
| PCT/GB2000/004572 WO2001040180A2 (en) | 1999-11-30 | 2000-11-30 | N-substituted 2-cyanopyrrolidines and their use as antidiabetic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0015788A true BR0015788A (pt) | 2002-07-16 |
Family
ID=10865461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0015788-0A BR0015788A (pt) | 1999-11-30 | 2000-11-30 | Agentes anti-diabéticos |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US6911467B2 (pt) |
| EP (1) | EP1351932A2 (pt) |
| JP (1) | JP2003515585A (pt) |
| KR (1) | KR20020063185A (pt) |
| CN (1) | CN1192020C (pt) |
| AU (1) | AU781060B2 (pt) |
| BR (1) | BR0015788A (pt) |
| CA (1) | CA2392713A1 (pt) |
| CZ (1) | CZ20021520A3 (pt) |
| EE (1) | EE200200273A (pt) |
| GB (1) | GB9928330D0 (pt) |
| HR (1) | HRP20020421B1 (pt) |
| HU (1) | HUP0203700A3 (pt) |
| IL (2) | IL149359A0 (pt) |
| MX (1) | MXPA02005253A (pt) |
| MY (1) | MY131036A (pt) |
| NO (1) | NO20022502D0 (pt) |
| PL (1) | PL355333A1 (pt) |
| RU (1) | RU2265012C2 (pt) |
| SK (1) | SK7212002A3 (pt) |
| UA (1) | UA75341C2 (pt) |
| WO (1) | WO2001040180A2 (pt) |
| ZA (1) | ZA200204283B (pt) |
Families Citing this family (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0109146D0 (en) * | 2001-04-11 | 2001-05-30 | Ferring Bv | Treatment of type 2 diabetes |
| US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US7232924B2 (en) | 2001-06-11 | 2007-06-19 | Xenoport, Inc. | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs |
| US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| CA2450579A1 (en) * | 2001-06-20 | 2003-01-03 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| ATE380175T1 (de) | 2001-06-27 | 2007-12-15 | Smithkline Beecham Corp | Pyrrolidine als dipeptidyl peptidase inhibitoren |
| DE10154689A1 (de) * | 2001-11-09 | 2003-05-22 | Probiodrug Ag | Substituierte Aminoketonverbindungen |
| JP4357293B2 (ja) | 2001-06-27 | 2009-11-04 | スミスクライン ビーチャム コーポレーション | ジペプチジルペプチダーゼ阻害剤としてのフルオロピロリジン類 |
| CN1723196A (zh) | 2001-06-27 | 2006-01-18 | 史密丝克莱恩比彻姆公司 | 作为二肽酶抑制剂的氟代吡咯烷 |
| GB0125446D0 (en) * | 2001-10-23 | 2001-12-12 | Ferring Bv | Novel anti-diabetic agents |
| US6861440B2 (en) | 2001-10-26 | 2005-03-01 | Hoffmann-La Roche Inc. | DPP IV inhibitors |
| JP4359146B2 (ja) | 2002-02-13 | 2009-11-04 | エフ．ホフマン−ラ ロシュ アーゲー | 新規なピリジン−およびピリミジン−誘導体 |
| ES2252656T3 (es) | 2002-02-13 | 2006-05-16 | F. Hoffmann-La Roche Ag | Nuevos derivados de piridina y quinolina. |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| WO2004050022A2 (en) * | 2002-12-04 | 2004-06-17 | Merck & Co., Inc. | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| CA2518465A1 (en) * | 2003-03-25 | 2004-10-14 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| CN1784220B (zh) | 2003-05-05 | 2011-08-03 | 前体生物药物股份公司 | 谷氨酰胺酰基和谷氨酸环化酶效应物的应用 |
| EP1961416B1 (en) | 2003-05-05 | 2013-01-23 | Probiodrug AG | Use of inhibitors of glutaminyl cyclase for treating psoriasis, rheumatoid arthritis or atherosclerosis. |
| WO2004098591A2 (en) | 2003-05-05 | 2004-11-18 | Probiodrug Ag | Inhibitors of glutaminyl cyclase and their use in the treatment of neurological diseases |
| JP2007511467A (ja) | 2003-05-14 | 2007-05-10 | タケダ サン ディエゴ インコーポレイテッド | ジペプチジルペプチダーゼインヒビター |
| WO2005000848A1 (en) | 2003-06-20 | 2005-01-06 | F. Hoffmann-La Roche Ag | Pyrido` 2, 1-a - isoquinoline derivatives as dpp-iv inhibitors |
| ATE437876T1 (de) | 2003-06-20 | 2009-08-15 | Hoffmann La Roche | Hexahydropyridoisochinoline als dpp-iv- inhibitoren |
| US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| KR20060041309A (ko) * | 2003-08-13 | 2006-05-11 | 다케다 야쿠힌 고교 가부시키가이샤 | ４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도 |
| US7205409B2 (en) | 2003-09-04 | 2007-04-17 | Abbott Laboratories | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
| EP1699777B1 (en) * | 2003-09-08 | 2012-12-12 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| EP1697342A2 (en) * | 2003-09-08 | 2006-09-06 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| BRPI0415409A (pt) | 2003-10-15 | 2006-12-05 | Probiodrug Ag | uso de efetuadores de ciclases de glutaminila e glutamato |
| AU2004290499C1 (en) | 2003-11-03 | 2011-02-24 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
| WO2005049022A2 (en) | 2003-11-17 | 2005-06-02 | Novartis Ag | Use of dipeptidyl peptidase iv inhibitors |
| RU2766487C2 (ru) | 2004-01-20 | 2022-03-15 | Новартис Аг | Композиция и способ прямого прессования |
| CA2554809C (en) | 2004-02-05 | 2014-04-29 | Probiodrug Ag | Novel n-alkyl thiourea- and thioamide-substituted imidazolyl inhibitors of glutaminyl cyclase |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| UA85871C2 (uk) | 2004-03-15 | 2009-03-10 | Такеда Фармасьютікал Компані Лімітед | Інгібітори дипептидилпептидази |
| US7687638B2 (en) * | 2004-06-04 | 2010-03-30 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| WO2006019965A2 (en) | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| US7842707B2 (en) | 2004-07-23 | 2010-11-30 | Nuada, Llc | Peptidase inhibitors |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| US7411093B2 (en) | 2004-12-20 | 2008-08-12 | Hoffman-La Roche Inc. | Aminocycloalkanes as DPP-IV inhibitors |
| EP1831165A1 (en) | 2004-12-20 | 2007-09-12 | F. Hoffmann-Roche AG | 4-aminopiperidine derivatives |
| JP2008524331A (ja) | 2004-12-21 | 2008-07-10 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼ阻害剤 |
| CN101103032B (zh) | 2004-12-24 | 2011-05-11 | 大日本住友制药株式会社 | 双环吡咯衍生物 |
| KR20080000665A (ko) * | 2005-04-22 | 2008-01-02 | 알란토스 파마슈티컬즈 홀딩, 인코포레이티드 | 디펩티딜 펩티다아제-ⅳ 억제제 |
| US7399869B2 (en) * | 2005-05-19 | 2008-07-15 | Genentech, Inc. | Fibroblast activation protein inhibitor compounds and methods |
| EP1910317B1 (en) | 2005-07-20 | 2013-07-03 | Eli Lilly And Company | 1-amino linked compounds |
| CA2617715A1 (en) * | 2005-08-11 | 2007-02-15 | F. Hoffmann-La Roche Ag | Pharmaceutical composition comprising a dpp-iv inhibitor |
| EP1760076A1 (en) * | 2005-09-02 | 2007-03-07 | Ferring B.V. | FAP Inhibitors |
| MY147393A (en) * | 2005-09-14 | 2012-11-30 | Takeda Pharmaceutical | Administration of dipeptidyl peptidase inhibitors |
| PT1931350E (pt) * | 2005-09-14 | 2014-02-12 | Takeda Pharmaceutical | Administração de inibidores de dipeptidil peptidase |
| TW200745079A (en) * | 2005-09-16 | 2007-12-16 | Takeda Pharmaceuticals Co | Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor |
| TW200745080A (en) * | 2005-09-16 | 2007-12-16 | Takeda Pharmaceuticals Co | Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor |
| CA2622642C (en) | 2005-09-16 | 2013-12-31 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| GB0525164D0 (en) | 2005-12-09 | 2006-01-18 | Xention Discovery Ltd | Compounds |
| GB0526291D0 (en) | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
| WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| WO2007112368A1 (en) * | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Preparation of (r)-3-aminopiperidine dihydrochloride |
| WO2007123686A2 (en) * | 2006-03-31 | 2007-11-01 | Point Therapeutics, Inc. | Dpp inhibitors and uses thereof |
| AU2007235876A1 (en) | 2006-04-12 | 2007-10-18 | Probiodrug Ag | Enzyme inhibitors |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| EP2540725A1 (de) | 2006-05-04 | 2013-01-02 | Boehringer Ingelheim International GmbH | Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| MX2009002772A (es) * | 2006-09-13 | 2009-05-28 | Takeda Pharmaceutical | Uso de 2-6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro- 2h-pirimidin-1-ilmetil-4-fluoro-benzonitrilo. |
| US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
| US8278345B2 (en) | 2006-11-09 | 2012-10-02 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| TW200838536A (en) * | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
| ATE554085T1 (de) | 2006-11-30 | 2012-05-15 | Probiodrug Ag | Neue inhibitoren von glutaminylcyclase |
| US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
| KR20120030570A (ko) | 2007-04-03 | 2012-03-28 | 미쓰비시 타나베 파마 코퍼레이션 | 디펩티딜 펩티다아제 4 저해 화합물과 감미료와의 병용 |
| EP2142514B1 (en) | 2007-04-18 | 2014-12-24 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
| US8338450B2 (en) * | 2007-09-21 | 2012-12-25 | Lupin Limited | Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors |
| CL2008003653A1 (es) | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. |
| MY155630A (en) * | 2008-03-05 | 2015-11-13 | Nat Health Research Institutes | Pyrrolidine derivatives |
| PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| DE102008062136B4 (de) | 2008-12-16 | 2012-05-03 | Kamamed Ug | Pharmazeutische Zusammensetzung auf Basis von Peptid aus Kamelmilch |
| CN102256976A (zh) | 2008-12-23 | 2011-11-23 | 贝林格尔.英格海姆国际有限公司 | 有机化合物的盐形式 |
| AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
| WO2010146597A1 (en) | 2009-06-18 | 2010-12-23 | Lupin Limited | 2-amino-2- [8-(dimethyl carbamoyl)- 8-aza- bicyclo [3.2.1] oct-3-yl]-exo- ethanoyl derivatives as potent dpp-iv inhibitors |
| JP5934645B2 (ja) | 2009-09-11 | 2016-06-15 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体 |
| KR20240090632A (ko) | 2009-11-27 | 2024-06-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료 |
| JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
| NZ602312A (en) | 2010-03-10 | 2014-02-28 | Probiodrug Ag | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
| WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
| CN102946875A (zh) | 2010-05-05 | 2013-02-27 | 贝林格尔.英格海姆国际有限公司 | 组合疗法 |
| WO2011161161A1 (en) | 2010-06-24 | 2011-12-29 | Boehringer Ingelheim International Gmbh | Diabetes therapy |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| EP2686313B1 (en) | 2011-03-16 | 2016-02-03 | Probiodrug AG | Benzimidazole derivatives as inhibitors of glutaminyl cyclase |
| US8883800B2 (en) | 2011-07-15 | 2014-11-11 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| JP6218811B2 (ja) | 2012-05-14 | 2017-10-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体 |
| JP6224084B2 (ja) | 2012-05-14 | 2017-11-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体 |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| EA021236B1 (ru) * | 2012-10-03 | 2015-05-29 | Дафот Энтерпраизес Лимитед | Nα-АЦИЛЬНЫЕ ПРОИЗВОДНЫЕ АМИНОАЦИЛ-2-ЦИАНОПИРРОЛИДИНА - ИНГИБИТОРЫ ПРОЛИЛЭНДОПЕПТИДАЗЫ И ДИПЕПТИДИЛПЕПТИДАЗЫ-IV, ОБЛАДАЮЩИЕ ГИПОГЛИКЕМИЧЕСКИМ, ПРОТИВОГИПОКСИЧЕСКИМ, НЕЙРОПРОТЕКТОРНЫМ И УЛУЧШАЮЩИМ КОГНИТИВНЫЕ ФУНКЦИИ ДЕЙСТВИЕМ |
| EP3110449B1 (en) | 2014-02-28 | 2023-06-28 | Boehringer Ingelheim International GmbH | Medical use of a dpp-4 inhibitor |
| EA201791982A1 (ru) | 2015-03-09 | 2020-02-17 | Интекрин Терапьютикс, Инк. | Способы лечения неалкогольной жировой болезни печени и/или липодистрофии |
| CN109310697A (zh) | 2016-06-10 | 2019-02-05 | 勃林格殷格翰国际有限公司 | 利格列汀和二甲双胍的组合 |
| WO2018162722A1 (en) | 2017-03-09 | 2018-09-13 | Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke | Dpp-4 inhibitors for use in treating bone fractures |
| JP2020515639A (ja) | 2017-04-03 | 2020-05-28 | コヒラス・バイオサイエンシズ・インコーポレイテッド | 進行性核上性麻痺の処置のためのＰＰＡＲγアゴニスト |
| ES2812698T3 (es) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
| EP4263535A1 (en) * | 2020-12-17 | 2023-10-25 | Astrazeneca AB | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides |
| CN115368344A (zh) * | 2022-08-22 | 2022-11-22 | 湖北科技学院 | 组氨酸类衍生物及其制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL111785A0 (en) * | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
| DE122010000020I1 (de) | 1996-04-25 | 2010-07-08 | Prosidion Ltd | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
| TW492957B (en) * | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
| US6319902B1 (en) * | 1997-08-22 | 2001-11-20 | Shionogi & Co., Ltd. | Peptide derivatives having thiazolyl-alanine residue |
| CO5150173A1 (es) * | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
| DE60021254T2 (de) * | 1999-03-15 | 2006-04-20 | AXYS Pharmaceuticals, Inc., South San Francisco | N-cyanomethylamide als protease inhibitoren |
| GB9906715D0 (en) * | 1999-03-23 | 1999-05-19 | Ferring Bv | Compositions for promoting growth |
| GB9906714D0 (en) | 1999-03-23 | 1999-05-19 | Ferring Bv | Compositions for improving fertility |
| US6172081B1 (en) * | 1999-06-24 | 2001-01-09 | Novartis Ag | Tetrahydroisoquinoline 3-carboxamide derivatives |
-
1999
- 1999-11-30 GB GBGB9928330.1A patent/GB9928330D0/en not_active Ceased
-
2000
- 2000-11-30 EP EP00977749A patent/EP1351932A2/en not_active Withdrawn
- 2000-11-30 MX MXPA02005253A patent/MXPA02005253A/es active IP Right Grant
- 2000-11-30 BR BR0015788-0A patent/BR0015788A/pt not_active Application Discontinuation
- 2000-11-30 HR HR20020421A patent/HRP20020421B1/xx not_active IP Right Cessation
- 2000-11-30 JP JP2001541866A patent/JP2003515585A/ja active Pending
- 2000-11-30 SK SK721-2002A patent/SK7212002A3/sk not_active Application Discontinuation
- 2000-11-30 AU AU15384/01A patent/AU781060B2/en not_active Ceased
- 2000-11-30 IL IL14935900A patent/IL149359A0/xx active IP Right Grant
- 2000-11-30 HU HU0203700A patent/HUP0203700A3/hu unknown
- 2000-11-30 RU RU2002117298/04A patent/RU2265012C2/ru not_active IP Right Cessation
- 2000-11-30 US US10/129,787 patent/US6911467B2/en not_active Expired - Fee Related
- 2000-11-30 UA UA2002054387A patent/UA75341C2/uk unknown
- 2000-11-30 CN CNB008164568A patent/CN1192020C/zh not_active Expired - Fee Related
- 2000-11-30 WO PCT/GB2000/004572 patent/WO2001040180A2/en not_active Ceased
- 2000-11-30 CZ CZ20021520A patent/CZ20021520A3/cs unknown
- 2000-11-30 PL PL00355333A patent/PL355333A1/xx not_active Application Discontinuation
- 2000-11-30 EE EEP200200273A patent/EE200200273A/xx unknown
- 2000-11-30 KR KR1020027006133A patent/KR20020063185A/ko not_active Abandoned
- 2000-11-30 CA CA002392713A patent/CA2392713A1/en not_active Abandoned
-
2002
- 2002-04-25 IL IL149359A patent/IL149359A/en not_active IP Right Cessation
- 2002-05-14 MY MYPI20021737A patent/MY131036A/en unknown
- 2002-05-27 NO NO20022502A patent/NO20022502D0/no not_active Application Discontinuation
- 2002-05-29 ZA ZA200204283A patent/ZA200204283B/xx unknown
-
2005
- 2005-04-15 US US11/106,594 patent/US7169806B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| UA75341C2 (en) | 2006-04-17 |
| US6911467B2 (en) | 2005-06-28 |
| AU1538401A (en) | 2001-06-12 |
| NO20022502L (no) | 2002-05-27 |
| US20050203031A1 (en) | 2005-09-15 |
| CZ20021520A3 (cs) | 2002-10-16 |
| AU781060B2 (en) | 2005-05-05 |
| HRP20020421B1 (en) | 2008-01-31 |
| US7169806B2 (en) | 2007-01-30 |
| IL149359A (en) | 2007-10-31 |
| CN1402706A (zh) | 2003-03-12 |
| PL355333A1 (en) | 2004-04-19 |
| CN1192020C (zh) | 2005-03-09 |
| WO2001040180A2 (en) | 2001-06-07 |
| CA2392713A1 (en) | 2001-06-07 |
| HRP20020421A2 (en) | 2004-02-29 |
| MXPA02005253A (es) | 2002-11-07 |
| HUP0203700A2 (hu) | 2003-03-28 |
| SK7212002A3 (en) | 2002-12-03 |
| HUP0203700A3 (en) | 2004-01-28 |
| WO2001040180A3 (en) | 2001-11-08 |
| EP1351932A2 (en) | 2003-10-15 |
| GB9928330D0 (en) | 2000-01-26 |
| JP2003515585A (ja) | 2003-05-07 |
| KR20020063185A (ko) | 2002-08-01 |
| ZA200204283B (en) | 2003-09-03 |
| MY131036A (en) | 2007-07-31 |
| IL149359A0 (en) | 2002-11-10 |
| NO20022502D0 (no) | 2002-05-27 |
| RU2265012C2 (ru) | 2005-11-27 |
| US20030096857A1 (en) | 2003-05-22 |
| EE200200273A (et) | 2003-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0015788A (pt) | Agentes anti-diabéticos | |
| DK1265606T3 (da) | Celleadhæsionsinhibitorer | |
| TR200200082T2 (tr) | MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi. | |
| BRPI0111596B8 (pt) | Composto piridona, processo de produção do composto, composição farmacêutica, e uso do dito composto | |
| NO20021399D0 (no) | Kazolinderivater og deres anvendelse som farmasöytika | |
| TR200200205T2 (tr) | MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi | |
| BR9806752A (pt) | Ftalazinonas. | |
| IL126610A0 (en) | N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3- one derivatives as factor xa inhibitors | |
| NL350075I2 (pt) | ||
| SE9904652D0 (sv) | Novel Compounds | |
| DK0725788T3 (da) | 2'-amido- og 2'-peptidomodificerede oligonukleotider | |
| DE60230127D1 (de) | Inhibitoren von integrin alpha-v-beta-6 | |
| CO5251427A1 (es) | Oxazolidinonas que tienen la fucion de sulfoximina | |
| NO974843L (no) | Benzimidazolforbindelser, farmasöytiske sammensetninger som inneholder forbindelsene og deres anvendelser | |
| BRPI0407841A (pt) | inibidores heterocìclicos de quinase | |
| BRPI0418255A (pt) | derivados de piperazina e piperidina n-substituìdos | |
| DK1077218T3 (da) | Peptidomimetiske forbindelser omfattende RGD-sekvenser, som er nyttige som integrininhibitorer | |
| BR9713207A (pt) | Derivados de 3-mercaptoacetilamino-1,5-substituìdo-2-oxo-azepan uteis como inibidores de metaloproteinase de matriz | |
| AR044175A1 (es) | Compuestos de cefemo | |
| GR3035205T3 (en) | Compounds related to the amidinium family, pharmaceutical compositions containing same, and uses thereof | |
| DK1377574T3 (da) | 6-phenylbenzonaphtyridiner | |
| NZ332597A (en) | Alkyloxyamino substituted fluoren-9-ones and their use as protein kinase c inhibitors | |
| BR0307016A (pt) | ácidos 3-(imidazolil)-2-alcoxipropanóicos | |
| TW350840B (en) | N-acylpiperazine derivative, antibacterial drug and anti-ulcer drug | |
| EA200600608A1 (ru) | Производные имидазопиридина как ингибиторы индуцируемой no-синтазы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] |
Free format text: DE ACORDO COM ART. 34 " II " DA LPI ( LEI 9279, DE 14/05/96 ) , O EXAME FICA SUSPENSO PARA QUE O REQUERENTE APRESENTE DOCUMENTOS NECESSARIOS A REGULARIZACAO DO PROCESSO E EXAME DO PEDIDO. |
|
| B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
| B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |